Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma

NCT00807495 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Diffuse Large B-cell Lymphoma
Mantle Cell Lymphoma
Burkitt's Lymphoma
T-cell Lymphoma, Excluding Primary Cutaneous T-cell Lymphoma
Transformed Follicular Lymphoma With ≥ 50% Diffuse Large Cell Component

Interventions

DRUG: Alisertib

Sponsor

Millennium Pharmaceuticals, Inc.